Energy expenditure regulation
Concerning this matter, previous publications have signified the massive accumulation of impaired mitochondria and protein occlusions in mouse renal cells after deficiency of autophagy (Kimura et al., 2011
Essential for hospital patients with gastrointestinal disorders, bowel surgery, alcoholism, or chronic illness
Abdel-Rahman M, Soliman ASH, Morsi MKS, Mehrez AMA
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions